Mupirocin Ointment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a fermentation-derived antibiotic substance whose principal component is pseudomonic acid A. The free acid is identified by CAS 12650-69-0, and the calcium salt dihydrate is identified by CAS 115074-43-6. No discrete model identifier is assigned; the veterinary API grade is defined by the certificate-of-analysis profile, particle size range, and microbial quality rather than by a commercial model number. The molecular formula C₂₆H₄₄O₉ corresponds to a molecular weight of 500.6 g/mol for the free acid, while the calcium salt dihydrate is approximately 1075.4 g/mol. The material is intended for downstream manufacture of tablets, injections, capsules, powders, granules, premixes, and solutions for veterinary use, provided that formulation-specific preformulation and stability studies are completed.

The API is controlled against current pharmacopoeial monographs and veterinary GMP guidance. Certificate-of-analysis parameters include appearance, infrared identification, HPLC assay, related substances, water content, residual solvents, residue on ignition, elemental impurities, microbial enumeration, and bacterial endotoxins where injectable or ophthalmic dosage forms are intended. Particle size is controlled by laser diffraction according to ISO 13320:2020 or USP <429>; the acceptance range is tied to the dosage form, with ointment and premix grades often requiring a D90 ≤ 20 µm to avoid grittiness and segregation.

Mupirocin differs from beta-lactam, macrolide, lincosamide, and fluoroquinolone veterinary antibiotics because it inhibits bacterial isoleucyl-tRNA synthetase, preventing incorporation of isoleucine into nascent proteins. This mechanism gives a narrow gram-positive spectrum and does not share target-site cross-resistance with beta-lactams or macrolides. The difference is not merely pharmacological; it also affects formulation choices, because mupirocin is a weak organic acid with pH-dependent aqueous solubility and is generally handled as a low-moisture, controlled-particle-size solid.

What Distinguishes a Veterinary-Specified Mupirocin API from Material Intended Only for Human Pharmacopoeial Use?

Veterinary API specifications are not automatically acceptable for human use, and the reverse is also true. The difference includes residual-solvent management under VICH GL18 rather than ICH Q3C alone, documentation of veterinary GMP, and often broader particle size or bulk density ranges that reflect incorporation into medicated feed and premix equipment. Table 1 lists the controls most commonly assessed during technical transfer.

Stability protocols for veterinary mupirocin API should follow VICH GL3 rather than ICH Q1A only. Batches are placed in long-term storage at 25 °C/60 % RH and accelerated storage at 40 °C/75 % RH in accordance with the applicable climatic zone. If the intended market includes tropical regions, 30 °C/65 % RH may be the long-term condition. The analytical methods are stability-indicating and include assay, related substances, and water content.

On pilot-scale dry blending lines, segregation of mupirocin calcium dihydrate from excipients is evaluated in bin blenders with capacities from 100 L to 600 L. Blend uniformity is sampled at 10 locations according to USP <905>, and an acceptance value ≤ 15 is commonly applied for low-dose veterinary tablets. If the Carr index determined by USP <616> exceeds 30, addition of colloidal silicon dioxide at 0.5–1.0 wt% is evaluated; the exact level is determined by flow function tests because excess glidant can reduce tablet tensile strength. Compression development is performed on an instrumented rotary tablet press with compaction pressure from 50 MPa to 150 MPa; compactability is reported as tensile strength versus solid fraction, not as a single hardness value. Granulation is selected when the active load is ≤ 2 wt% because low-dose direct compression can produce content uniformity failures under high-speed press conditions.

Thermal and Moisture Stress During Aqueous Processing of Mupirocin

Aqueous processing of mupirocin introduces pH-dependent solubility and hydrolysis risk. The free acid is weakly acidic, so solubility increases as pH rises, but alkaline conditions above pH 7.5 can accelerate ester hydrolysis. Preformulation buffers such as phosphate at pH 6.8–7.4 and ionic strength ≤ 0.1 M are screened. For solution dosage forms, the drug substance is dissolved under controlled temperature, typically 20–25 °C, and the solution is protected from prolonged heating. If terminal steam sterilization at 121 °C for 15 min is considered, forced degradation data are required because published stability data for mupirocin under this aqueous sterilization cycle are limited. Sterile filtration through a 0.22 µm PVDF or PES membrane is an alternative, but the low aqueous solubility of mupirocin free acid may reduce throughput and require a solubility-enhancing excipient.

Ointment manufacture avoids many aqueous instability issues but introduces particle size constraints. The active phase is dispersed in the base using an ointment mill or high-shear disperser; fineness of dispersion is checked by microscopy under 100× magnification. If the drug substance contains particles above the specified D90, grittiness may appear in the finished ointment. A three-roll mill is commonly used for polishing the dispersion, with roll gaps adjusted from 50 µm to 150 µm until the dispersion passes the compendial or internal microscopy limit.

Before sterile filtration is selected as the terminal sterilization method, the viscosity and surface tension of the formulated solution are measured to predict flux through the filter. A formulation with viscosity above 20 mPa·s at 25 °C is generally unsuitable for high-speed filtration without pressure adjustment; rheological measurement follows ISO 3219 or USP <911>. The selected container-closure system is validated per USP <1207>; particulate matter is controlled according to USP <788>. For injectable products, bacterial endotoxin limits are derived from the maximum intended dose using USP <85>; the API must meet the assigned limit before formulation, and the finished product is tested for sterility according to USP <71>.

Medicated premix and granule operations require that the active particle size distribution be matched to the carrier particle size distribution to prevent segregation. A mixing CV ≤ 5 % at 10 sampling points is often used as an internal release criterion when whole-feed HPLC assay is performed. If the premix is intended for pelletized feed, the mupirocin component is evaluated for stability during conditioning at temperatures up to 70 °C and moisture addition up to 15 %; published stability data under hot pelleting conditions are limited and must be generated case by case.

When Mupirocin Calcium Salt Emerges as the Preferred Solid-State Form for Dry Blends

For low-dose tablet and capsule formulations, the calcium salt dihydrate is evaluated as an alternative to the free acid when reduced solubility or modified dissolution is required. The calcium salt form has different water uptake, bulk density, and particle morphology; these properties are confirmed by powder X-ray diffraction and differential scanning calorimetry. If the material is received with water content above 0.5 %, vacuum tray drying at 40–45 °C and ≤ 10 kPa is applied until loss on drying by USP <731> reaches the target. Table 2 summarizes the dosage-form-specific API attributes.

Roller compaction is used when the milled active has poor flow. It is performed on a roller compactor with roll pressure from 4 MPa to 12 MPa, roll speed from 2 rpm to 8 rpm, and screen milling after compaction; fines below 75 µm are controlled because excessive fines can shift the particle size distribution and reduce flow. Solid-state characterization includes X-ray powder diffraction and differential scanning calorimetry; if the calcium salt dihydrate is converted to an amorphous form by milling, the material may show increased hygroscopicity and reduced chemical stability. The drying temperature must remain below the dehydration temperature of the dihydrate; the dehydration endotherm is observed by differential scanning calorimetry, but the exact onset must be batch-specific.

Stability-indicating HPLC methods for mupirocin API typically manage related substances such as pseudomonic acid B, C, and D. The method is validated for specificity, linearity, accuracy, and precision according to current ICH Q2 and VICH guidance. The assay is expressed on the anhydrous, solvent-free basis and reported with the same significant figures as the pharmacopoeial monograph. If the API is exposed to temperature above the validated storage range, forced degradation samples are analyzed for the principal degradation product; no release of the batch is made unless the impurity profile remains within the approved specification. Mass balance is calculated as the sum of assay and total related substances; if mass balance is outside 97.0–103.0 %, the analytical method is investigated for unaccounted degradants. Reserve samples are retained according to veterinary GMP and local regulations. The API is released only after the quality unit verifies that the batch record, analytical data, and traceability documentation are complete.